<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462707</url>
  </required_header>
  <id_info>
    <org_study_id>A8641021</org_study_id>
    <nct_id>NCT02462707</nct_id>
  </id_info>
  <brief_title>A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase 1 Study Of Pf-03084014 To Evaluate Safety And Pharmacokinetics In Japanese Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the recommended Phase 2 dose for PF-03084014
      single-agent administration in Japanese patients with advanced solid tumors. Pharmacokinetics
      and the overall safety profile of PF-03084014 will also be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First-cycle Dose Limiting Toxicities</measure>
    <time_frame>during the first 28 days from the first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8, 24, 48, 96, 120 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc interval</measure>
    <time_frame>from the first dose to the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8, 24, 48, 96, 120 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8, 24, 48, 96, 120 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8, 24, 48, 96, 120 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8, 24, 48, 96, 120 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution at steady state (Vss/F)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8, 24, 48, 96, 120 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Plasma Trough Concentration (Cmin)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8, 24, 48, 96, 120 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Serum Concentration at steady state (Cav)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8, 24, 48, 96, 120 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio (Rac)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8 hours post-dose on Day 1 and Day 21</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>PF-03084014</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03084014</intervention_name>
    <description>gamma-secretase inhibitor, formulated in tablets for oral administration containing 10 mg, 50 mg and 100 mg. Patient will receive 80 mg, 100 mg or 150 mg twice daily of PF-03084014 with continuous dosing schedule</description>
    <arm_group_label>PF-03084014</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological diagnosis of advanced solid tumors that is resistant to
             standard therapy or for which no standard therapy is available.

          -  Age ≥18 years.

          -  ECOG Performance Status (PS) must be 0 or 1.

          -  Adequate Bone Marrow Function

          -  Adequate Renal Function

          -  Adequate Liver Function

          -  Resolved acute effects of any prior therapy to baseline severity or Grade ≤1

        Exclusion Criteria:

          -  Patients with known brain metastases

          -  Major surgery within 4 weeks of starting study treatment

          -  Radiation therapy within 2 weeks of starting study treatment

          -  Systemic anti cancer therapy within 2 weeks (4 weeks for antibody) of starting study
             treatment

          -  Previous high dose chemotherapy requiring stem cell rescue

          -  Prior irradiation to &gt;25% of the bone marrow

          -  Prior treatment with a Notch signal inhibitor

          -  Known malabsorption syndrome or other condition that may impair absorption of study
             medication

          -  Any of the following in the previous 6 months: myocardial infarction, severe/unstable
             angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure,
             cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism

          -  Current use or anticipated need for known strong and/or moderate CYP3A4 inhibitors

          -  Current use or anticipated need for known strong CYP3A4 inducers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <last_update_submitted>October 6, 2015</last_update_submitted>
  <last_update_submitted_qc>October 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

